Miranda joined the Conway group in March 2024 as a joint student with the Houk group. She is currently working on in computational drug design and protein modeling of Immunomodulatory imide drugs (IMiDs) bind to the E3 ubiquitin ligase cereblon, recruiting zinc finger (ZF)-containing proteins such as IKZF1 and IKZF3. Her research focus on identifying and optimizing iMiD analogs affinities to guide iMiD design for target protein degradation as a therapeutic candidates for oncology. In her spare time, she also enjoys playing badminton and snowboarding.